中国实用儿科杂志2026，Vol.41Issue(4)：276-285,10.DOI:10.19538/j.ek2026040603
《NASPGHAN儿童炎症性肠病治疗药物监测目标立场文件》2025版解读及与中国指南对比分析
Interpretation of the 2025 NASPGHAN position paper on therapeutic drug monitoring targets in pediatric inflammatory bowel disease and comparison with the 2025 Chinese guideline
高慧中 1何玮梅 1张敏敏 1张晨美 1赵仕国1
作者信息
- 1. 浙江大学医学院附属儿童医院 儿童少年健康与疾病国家临床医学研究中心,浙江 杭州 310052
- 折叠
摘要
Abstract
In the application of biologic agents for pediatric inflammatory bowel disease(IBD),accelerated drug clearance and immunogenicity often lead to subtherapeutic exposure during induction therapy.Even when short-term clinical response or clinical remission is achieved,failure of early trough concentrations to reach target may still increase the risk of subsequent loss of efficacy and loss of response.This article interprets the North American Society for Pediatric Gastroenterology,Hepatology and Nutrition(NASPGHAN)position paper on therapeutic drug monitoring(TDM)in pediatric IBD(2025 edition)to achieve a proactive exposure target-driven framework.We then compared these recommendations with the Practice Guideline for TDM in Pediatric IBD(2025)by Chinese Medical Association,focusing on target drug concentrations for anti-tumor necrosis factor-α agents and other biologics,optimal timing for TDM,stratified management of anti-drug antibodies,and dose-intensification strategies.Key differences in monitoring approaches for high-risk phenotypes-including acute severe ulcerative colitis,perianal Crohn's disease,and very early-onset IBD-are summarized to provide reference for clinical practice in China.关键词
儿童炎症性肠病/治疗药物监测/生物制剂/英夫利昔单抗/阿达木单抗/维得利珠单抗/乌司奴单抗Key words
pediatric inflammatory bowel disease/therapeutic drug monitoring/biologics/infliximab/adalimumab/vedolizumab/ustekinumab分类
医药卫生引用本文复制引用
高慧中,何玮梅,张敏敏,张晨美,赵仕国..《NASPGHAN儿童炎症性肠病治疗药物监测目标立场文件》2025版解读及与中国指南对比分析[J].中国实用儿科杂志,2026,41(4):276-285,10.
